Ayala Pharmaceuticals, Inc. (ADXS)
OTCMKTS · Delayed Price · Currency is USD
0.0347
0.00 (0.00%)
Aug 1, 2025, 9:46 AM EDT
Ayala Pharmaceuticals Company Description
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers.
The company’s lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Ayala Pharmaceuticals, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Kenneth Berlin |
Contact Details
Address: 1007 North Orange Street Wilmington, Delaware 19802 United States | |
| Phone | 857 444 0553 |
| Website | ayalapharma.com |
Stock Details
| Ticker Symbol | ADXS |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US0076244062 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kenneth A. Berlin J.D. | Chief Executive Officer, President and Director |
| Irit Klipper-Avni M.A. | Vice President of Human Resources |
| Dana Gelbaum M.B.A., M.Sc. | GM and Chief Business Officer |